We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently.
As the broader market continues to rise this year, we thought it would be interesting to highlight some stocks that have seen significant insider buying recently. Insiders—such as executives and directors—often have valuable insights into a company’s strategy, plans, and future initiatives. For instance, when a CEO or CFO invests their own money to purchase company shares, it can be seen as a strong vote of confidence in the company’s prospects. When an insider makes a substantial financial commitment, it often signals an even higher level of confidence in the company’s future performance.
Why should we be interested in insider trading activity? While both insider selling and buying can be driven by various motives, it is important to consider these moves within the broader context of the company’s fundamentals, industry trends, and overall market conditions. That’s why due diligence before any investment is of the utmost importance. However, insider trading activity in combination with other relevant determinants can offer valuable insights into a company’s capabilities, helping investors make more informed investment decisions.
What are some of the stocks that have seen the most insider investment recently? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where each individual insider purchase was valued at $2 million or more. This means the total value of insider purchases over the same period (last 60 days) could be higher, but only larger purchases were considered in the search.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
With each stock, we note the value of acquired shares, which refers to the value of shares acquired through individual insider purchases worth at least $2 million each.
Mila Supinskaya Glashchenko/Shutterstock.com
Metsera, Inc. (NASDAQ:MTSR)
Value Of Shares Acquired: $94,219,956.00
Market Cap: $3.31 billion
Sixth among 10 stocks insiders spent the most money on recently is Metsera, a clinical-stage biotechnology company. Metsera is engaged in the development of injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. The New York City-headquartered company is working on a comprehensive portfolio of therapies with the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.
On February 3, three insiders purchased a total of around $94.22 million worth of Metsera shares during the company’s initial public offering. Insiders acquired shares at a price of $18 per share. The company raised $257 million during its IPO, pricing shares above its targeted range. Currently, the stock is trading at $32.08 per share, having gained 21.06% since then.
In January, the company announced positive data from a 12-week Phase 2a clinical trial of its leading candidate – MET-097i, a potential once-monthly injectable treatment for obesity. The results revealed that MET-0971 helped participants lose weight (with some losing 20% of their body weight), and was well tolerated with mild side effects. The company plans further studies in 2025.
“MET-097i has the potential to be a foundational therapy for people with obesity and overweight, by virtue of its effectiveness, compelling tolerability profile and flexible options for dosing, including titration-free weekly dosing and monthly dosing,” commented John Buse, M.D., Verne S. Caviness Distinguished Professor and Director of the UNC Diabetes Center at University of North Carolina School of Medicine.
Currently, there is no analyst coverage available for this stock as it recently went public and coverage typically begins after a company has been listed for a certain period of time. We should expect analyst reports as the company matures in the market.
Overall, MTSR ranks 6th on our list of stocks insiders spent the most money on recently. While we acknowledge the potential of MTSR our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MTSR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
